In a recent post on the IVI-sponsored Health Affairs blog series, Ameet Sarpatwari and Michael Sinha discuss why the 21st Century Cures legislation increases risk of patient harm. Among the issues they highlight are uncertainty around funding — especially for prevention, research, and regulatory science — and the loosening of evidence standards for FDA approvals.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
